The Pathway to Cancer Cachexia: MicroRNA-Regulated Networks in Muscle Wasting Based on Integrative Meta-Analysis
, Geysson Javier Fernandez 1, Sarah Santiloni Cury 1, Diogo de Moraes 1, Jakeline Santos Oliveira 1, Grasieli de Oliveira 1, Maeli Dal-Pai-Silva 1, PatrÃcia Pintor dos Reis 2,3 and Robson Francisco Carvalho 1,*Round 1
Reviewer 1 Report
The study provides insight into novel signalling pathways that are potential novel targets for therapy of cachexia as a systemic syndrome. Especially, the finding that CXCL12 and systemic inflammation are associated to cachexia is crucial. However, mechanisms that might be involved in metabolic driven regulation of adaptive and innate immune fate decision and funtion by the CXCL12 and CXCR4 axis and how these might mediate cachexia progression should be discussed. The fact that inflammation is a risk factor for cachexia is crucial to understand the syndrome in many chronic inflammatory and metabolic diseases and to identify novel targets for prevention of cachexia in patients wit these diseases.
Author Response
Response 1:
Thank you for the comments on our manuscript. We have now included in our discussion the required information regarding the CXCL12 and CXCR4 axis in muscle wasting during cancer cachexia, as demonstrated by Martinelli et al., 2016 [1] .
Reference
Martinelli, G.B.; Olivari, D.; Re Cecconi, A.D.; Talamini, L.; Ottoboni, L.; Lecker, S.H.; Stretch, C.; Baracos, V.E.; Bathe, O.F.; Resovi, A.; et al. Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. Oncogene 2016, 35, 6212–6222.
Author Response File: 
Author Response.pdf
Reviewer 2 Report
This is an interesting manuscript on cancer cachexia.
It provides relevant information about potential therapeutic targets that required additional studies.
I consider it acceptable for publication in this format.
Author Response
Dear reviewer,
We appreciate the comments on our manuscript.
Author Response File: Author Response.pdf
